HalfLifeDBEvidence before certainty.

5-MeO-DMT evidence profile

A controlled phase 1 trial reports rapid absorption and a mean terminal half-life below 27 minutes for one intranasal benzoate formulation.

Category: psychedelic · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model statusNo curve publishedCurrent sources do not support one defensible human input
Evidence boundarySource note onlyNo animal, forensic, mixture, or proxy value is presented as a human half-life
Model scopeNot modeledThe profile explains what the available records can and cannot establish
References2Linked studies, labels, reviews, or identity records described below

5-MeO-DMT: evidence and interpretation notes

Why HalfLifeDB does not plot 5-MeO-DMT

A controlled phase 1 trial reports rapid absorption and a mean terminal half-life below 27 minutes for one intranasal benzoate formulation. Because the publication states a bound rather than one universal value, and formulation matters, this page keeps the finding in prose instead of converting it into an exact curve.

What each source contributes

  • PubChem: 5-MeO-DMT. This identity record confirms names and compound identity and does not supply a human half-life.
  • Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.

For 5-MeO-DMT, the decision to withhold a curve turns on the limits visible in Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. This human pharmacokinetic record adds measured route, analyte, and population context, but it does not become a universal result.

What evidence would change the page

Before 5-MeO-DMT could move from an evidence note to a chart, a study would need serial human measurements of the parent compound after a defined route, enough sampling to characterize elimination, and a population narrow enough to label honestly. That is a different evidence package from Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.

InterpretationCategory context and evidence limits

psychedelic context

Psychedelic duration is shaped by pharmacodynamics as well as pharmacokinetics, so subjective effects may not track a simple elimination curve.

  • The curve does not predict psychological effects or functional safety.
  • Metabolites and downstream receptor activity are not separately modeled.
  • Published estimates may come from small or specialized study populations.
EvidenceSource trail and model decision

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

1 PubMed0 PMC0 DailyMed1 PubChem
  1. Identity record PubChem Compound Summary: 5-MeO-DMT.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
  2. Research abstract PubMed: Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.
    Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.